PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
89.93%
Revenue growth above 1.5x CVE's 19.35%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
309.76%
Gross profit growth above 1.5x CVE's 18.64%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
971.26%
EBIT growth above 1.5x CVE's 9.80%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
971.26%
Operating income growth above 1.5x CVE's 9.80%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
663.07%
Net income growth above 1.5x CVE's 49.66%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
661.70%
EPS growth above 1.5x CVE's 50.00%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
654.26%
Diluted EPS growth above 1.5x CVE's 50.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.08%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
1.24%
Slight or no buyback while CVE is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
23.17%
Dividend growth under 50% of CVE's 178.30%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
96.20%
OCF growth at 75-90% of CVE's 118.24%. Bill Ackman would demand better working capital management or cost discipline.
255.98%
FCF growth similar to CVE's 248.30%. Walter Schloss would attribute it to parallel capital spending and operational models.
192.62%
10Y revenue/share CAGR above 1.5x CVE's 85.90%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
161.01%
5Y revenue/share CAGR at 75-90% of CVE's 187.15%. Bill Ackman would encourage strategies to match competitor’s pace.
95.23%
3Y revenue/share CAGR at 75-90% of CVE's 118.23%. Bill Ackman would expect new product strategies to close the gap.
21.95%
10Y OCF/share CAGR 1.25-1.5x CVE's 17.99%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
366.46%
5Y OCF/share CAGR above 1.5x CVE's 35.81%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
59.30%
3Y OCF/share CAGR 1.25-1.5x CVE's 45.66%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
152.43%
Net income/share CAGR 1.25-1.5x CVE's 135.47%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
210.19%
Positive 5Y CAGR while CVE is negative. John Neff might view this as a strong mid-term relative advantage.
333.70%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-51.25%
Negative equity/share CAGR over 10 years while CVE stands at 1.03%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-35.07%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-37.58%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
-75.07%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
245.88%
5Y dividend/share CAGR above 1.5x CVE's 99.08%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
174.91%
3Y dividend/share CAGR above 1.5x CVE's 116.19%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
6.23%
Our AR growth while CVE is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
No Data
No Data available this quarter, please select a different quarter.
0.15%
Asset growth well under 50% of CVE's 0.43%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
24.37%
BV/share growth above 1.5x CVE's 7.77%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-15.45%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-5.15%
We cut SG&A while CVE invests at 9.55%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.